Jennifer Yen

6.9k total citations · 1 hit paper
34 papers, 996 citations indexed

About

Jennifer Yen is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Jennifer Yen has authored 34 papers receiving a total of 996 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cancer Research, 11 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Jennifer Yen's work include Cancer Genomics and Diagnostics (15 papers), Gastric Cancer Management and Outcomes (4 papers) and PARP inhibition in cancer therapy (4 papers). Jennifer Yen is often cited by papers focused on Cancer Genomics and Diagnostics (15 papers), Gastric Cancer Management and Outcomes (4 papers) and PARP inhibition in cancer therapy (4 papers). Jennifer Yen collaborates with scholars based in United States, United Kingdom and Singapore. Jennifer Yen's co-authors include Alice R. Mao, Raphael Bernier, Derek L. Stemple, Amanda Hall, Neha Wali, Ross Kettleborough, Fredericus J. M. van Eeden, Christopher M. Dooley, Edwin Cuppen and Richard J. Gibbons and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Applied and Environmental Microbiology.

In The Last Decade

Jennifer Yen

32 papers receiving 980 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A systematic genome-wide analysis of zebrafish protein-coding gene function

2013 445 citations Ross Kettleborough, Elisabeth M. Busch‐Nentwich et al. Nature profile →

Peers

Countries citing papers authored by Jennifer Yen

Since Specialization

Citations

This map shows the geographic impact of Jennifer Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Yen more than expected).

Fields of papers citing papers by Jennifer Yen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Yen. The network helps show where Jennifer Yen may publish in the future.

Co-authorship network of co-authors of Jennifer Yen

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Yen. A scholar is included among the top collaborators of Jennifer Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Yen. Jennifer Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib 2023 ·Clinical Cancer Research ·Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, (unknown), Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Erica L. Carpenter, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss	10
2	The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib. 2023 ·Journal of Clinical Oncology ·Timothy J. Brown, Arielle Yablonovitch, Jennifer Yen, Lesli A. Kiedrowski, Erica L. Carpenter, Katherine L. Nathanson, Susan M. Domchek, (unknown)	1
3	Abstract 3135: Validation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay 2023 ·Cancer Research ·Jennifer Yen, (unknown), (unknown), Katie Quinn, (unknown), (unknown), Carin R. Espenschied, (unknown), (unknown), Han‐Yu Chuang	1
4	Abstract P5-03-18: Co-occurring alterations in PALB2 germline carriers identified by liquid biopsy in patients with advanced breast cancer 2023 ·Cancer Research ·Nan Chen, Rita Nanda, Frederick M. Howard, Neelima Vidula, Jennifer Yen, Leylah Drusbosky, (unknown)	0
5	Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC 2021 ·OncoTargets and Therapy ·Ling Peng, Kui Xiao, Jian Cui, Xianghua Ye, Yongchang Zhang, Li Mao, Giovanni Selvaggi, Jennifer Yen, Justin Stebbing	4
6	Abstract 537: NTRK1 fusion detection from clinical cfDNA NGS using a de novo fusion caller 2021 ·Cancer Research ·Arielle Yablonovitch, Sante Gnerre, Jennifer Yen, Scott A. Shell, Elena Helman, Stephen R. Fairclough, Rebecca J. Nagy, Justin I. Odegaard, Darya Chudova, AmirAli Talasaz	3
7	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations 2019 ·Clinical Cancer Research ·Thereasa A. Rich, Karen L. Reckamp, Young Kwang Chae, Robert C. Doebele, Wade T. Iams, Michael S. Oh, Victoria M. Raymond, Richard B. Lanman, Jonathan W. Riess, Thomas E. Stinchcombe, Vivek Subbiah, David R. Trevarthen, Stephen R. Fairclough, Jennifer Yen, Oliver Gautschi	68
8	Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). 2019 ·Journal of Clinical Oncology ·Daniel V.T. Catenacci, Kian‐Huat Lim, Hope E. Uronis, Yoon‐Koo Kang, Matthew Chau Hsien Ng, Philip J. Gold, Peter C. Enzinger, Keun Wook Lee, Jill Lacy, Se Hoon Park, Jennifer Yen, Justin I. Odegaard, Aleksandra Franovic, Jan Baughman, (unknown), Francine Chen, Paul A. Moore, Tony T. Wu, Jan Davidson‐Moncada, Yung‐Jue Bang	16
9	Abstract 2509: Analysis of clonal hematopoiesis-associated mutations in the cell-free DNA of advanced cancer patients 2019 ·Jennifer Yen, Katie Quinn, Elena Helman, (unknown), Tracy Nance, Ariel Jaimovich, Kimberly C. Banks, Aleksandra Franovic, (unknown), John Latham, Arielle Yablonovitch, Marcin Sikora, Stephen R. Fairclough, Darya Chudova, Richard B. Lanman, AmirAli Talasaz	3
10	Comparison of the novel ARCHITECT procalcitonin assay with established procalcitonin assay systems 2018 ·Practical Laboratory Medicine ·Andrew Soh, Lutz Binder, (unknown), (unknown), Guillaume Lefèvre, (unknown), (unknown), (unknown), Oytun Portakal, (unknown), Jennifer Yen, (unknown), Agim Beshiri	15
11	Abstract 5603: Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research 2018 ·Cancer Research ·Elena Helman, Carlo G. Artieri, James V. Vowles, Jennifer Yen, Tracy Nance, Marcin Sikora, (unknown), (unknown), Stefanie Mortimer, Darya Chudova, Justin I. Odegaard, Richard B. Lanman, AmirAli Talasaz	15
12	Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). 2018 ·Journal of Clinical Oncology ·Daniel V.T. Catenacci, Haeseong Park, Hope E. Uronis, Yoon‐Koo Kang, Jill Lacy, Peter C. Enzinger, Se Hoon Park, Keun Wook Lee, Matthew Chau Hsien Ng, Philip J. Gold, Jennifer Yen, Aleksandra Franovic, Ronan J. Kelly, (unknown), Daner Li, John Muth, Jan Baughman, Sam Pyo Hong, Jan Davidson‐Moncada, Yung‐Jue Bang	12
13	A variant by any name: quantifying annotation discordance across tools and clinical databases 2017 ·Genome Medicine ·Jennifer Yen, Sarah Garcia, (unknown), Jason Harris, Stephen A. Chervitz, Massimo Morra, John West, Richard Chen, Deanna M. Church	51
14	Risk Factors for Venous Thromboembolism in Pediatric Trauma Patients and Validation of a Novel Scoring System: The Risk of Clots in Kids With Trauma Score* 2016 ·Pediatric Critical Care Medicine ·Jennifer Yen, Kyle J. Van Arendonk, Michael B. Streiff, (unknown), F. Dylan Stewart, (unknown), Richard E. Thompson, Elliott R. Haut, Clifford M. Takemoto	44
15	Zebrafish models of cancer: progress and future challenges 2014 ·Current Opinion in Genetics & Development ·Jennifer Yen, Richard M. White, Derek L. Stemple	41
16	A systematic genome-wide analysis of zebrafish protein-coding gene function breakdown → 2013 ·Nature ·Ross Kettleborough, Elisabeth M. Busch‐Nentwich, Steven Harvey, Christopher M. Dooley, Ewart de Bruijn, Fredericus J. M. van Eeden, Ian M. Sealy, Richard White, Colin Herd, Isaäc J. Nijman, (unknown), (unknown), Catherine M. Scahill, Richard J. Gibbons, Neha Wali, Samantha Carruthers, Amanda Hall, Jennifer Yen, Edwin Cuppen, Derek L. Stemple	445
17	α-Galactosidase A-Tat Fusion Enhances Storage Reduction in Hearts and Kidneys of Fabry Mice 2010 ·Molecular Medicine ·Koji Higuchi, Makoto Yoshimitsu, Xin Fan, Xiaoxin Guo, (unknown), Jennifer Yen, Chuwa Tei, Toshihiro Takenaka, Jeffrey A. Medin	12
18	Psychopathology, Families, and Culture: Autism 2010 ·Child and Adolescent Psychiatric Clinics of North America ·Raphael Bernier, Alice R. Mao, Jennifer Yen	110
19	Review of Proposed Changes in Child and Adolescent Psychiatry Diagnostic Criteria for DSM-Version 5 2010 ·Alice R. Mao, Jennifer Yen	3
20	Use of Purified Clostridium difficile Spores To Facilitate Evaluation of Health Care Disinfection Regimens 2010 ·Applied and Environmental Microbiology ·Trevor D. Lawley, Simon Clare, (unknown), David Goulding, Jennifer Yen, Claire Raisen, Cordelia Brandt, Jon Lovell, Fiona J. Cooke, Taane G. Clark, Gordon Dougan	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact